Drugs / RUXOTEMITIDE
RUXOTEMITIDE
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01986426 | Nov 2013 → Apr 2018 | head and neck cancer, lymphoma, melanoma, triple-negative breast carcinoma | Lytix Biopharma AS | Completed | No outcome recorded |
| Phase 1 | NCT01223209 | Aug 2010 → Dec 2011 | carcinoma | Lytix Biopharma AS | Completed | No outcome recorded |
| Phase 1 | NCT01058616 | Jan 2010 → Jan 2013 | — | Lytix Biopharma AS | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06651151 | Nov 2024 → May 2026 overdue | melanoma | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04796194 | Nov 2021 → Feb 2025 | melanoma | Lytix Biopharma AS | Completed | No outcome recorded |
| Phase 2 | NCT03725605 | Dec 2018 → Jul 2021 | soft tissue sarcoma | Lytix Biopharma AS | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Lytix Biopharma AS | Results Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab oslobors.no ↗
Antitumor activity was observed in heavily pretreated patients with advanced melanoma and metastatic TNBC, two populations with limited therapeutic options. |
| 2026-05-06 | Lytix Biopharma AS | Results New Phase II Study Data from Lytix Biopharma’s Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma oslobors.no ↗
The data suggests a potential abscopal effect of VP-315 in the treatment of basal cell carcinoma (BCC), as evidenced by reductions in the size of untreated, non-injected lesions. |
| 2026-04-21 | Lytix Biopharma AS | Results Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma oslobors.no ↗
Treatment with ruxotemitide in combination with pembrolizumab demonstrated clinically meaningful antitumor activity and a manageable safety profile in this difficult-to-treat population. |
| 2025-11-11 | Lytix Biopharma AS | Results Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital oslobors.no ↗
An even stronger pathological complete response (pCR), meaning no remaining viable tumor cells, was achieved in 44% of patients. |
| 2025-11-11 | Lytix Biopharma AS | Results Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhospitalet oslobors.no ↗
Patologisk komplett respons (pCR) observert i 44 % av de første ni evaluerbare pasientene (13 inkludert totalt), ingen pasienter har fått tilbakefall så langt. |
| 2025-11-10 | Lytix Biopharma AS | Results New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide oslobors.no ↗
The immunological analyses from Verrica’s Phase II study in basal cell carcinoma (BCC) demonstrated strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, alongside a marked reduction in immunosuppressive T-regulatory cells in the tumor microenvironment. |
All press releases naming this drug 10 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RUXOTEMITIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297628 ↗ |
| Known as | Kkwwkkw-.beta.-phenyl-fk-nh2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297628 ↗ |
| Known as | Kkwwkkwdipk-nh2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297628 ↗ |
| Known as | LTX-315 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04796194 ↗ |
| Known as | Oncopore | “LTX-315 (Oncopore™)” NCT01058616 ↗ |
| Known as | Ruxotemitida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297628 ↗ |
| Modality | Peptide | “LTX-315 a lytic-peptide that has shown effect in animal models to kill cancer tumours” NCT01058616 ↗ |
| Route | Other | “LTX-315 injected directly into transdermally accessible tumours” NCT01058616 ↗ |